In fact, we found that patients with adenocarcinoma harboring somatic mutations of EGFR, CTLA4, PDCD1LG2, or ZEB2 that only underwent surgical treatment and developed brain metastases may have the worst prognosis (8,9). This evidence concerns the gene EGFR and adenocarcinoma.